Skip to content

Triclosan

DERMATOLOGICALS

OfmFDA approvedATC D08AE04ATC D09AA06

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Triclosan is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1997. DrugCentral lists 13 molecular targets, including fabI, ENR and fabI.

  • Approval status: ofm (first approved 1997 by the FDA).
  • Molecular targets: fabI, ENR, fabI and CBR1 (13 listed in DrugCentral).
  • ATC code: D08AE04 (Phenol and derivatives).
  • Molecular formula: C12H7Cl3O2; molecular weight 289.54 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Contraindications (5)

  • Conduction disorder of the heart
  • Decreased respiratory function
  • Denuded skin
  • Open wound
  • Seizure disorder

Mechanism & targets

Molecular targets (13)

TargetGeneActionActivity
Enoyl-acyl-carrier protein reductasefabIunknownKi 10.28
Enoyl-acyl carrier reductase; Enoyl-acyl carrier reductase ENRENRunknownIC50 7.82
Enoyl-[acyl-carrier-protein] reductase [NADPH]fabIunknownIC50 7.23
Carbonyl reductase [NADPH] 1CBR1unknownKi 7.22
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabIfabIunknownIC50 7.15
Enoyl-[acyl-carrier-protein] reductase [NADH]inhAunknownKi 6.70
Enoyl-ACP reductaseFabIunknownIC50 6.70
Enoyl-[acyl-carrier-protein] reductase [NADH]inhAunknownKi 6.70
Enoyl-[acyl-carrier-protein] reductase [NADH] FabIfabIinhibitorIC50 6.37
TransthyretinTTRunknownKd 6.32
Enoyl-[acyl-carrier-protein] reductase [NADH] FabIfabIunknownIC50 6.30
Enoyl-[acyl-carrier-protein] reductase [NADH]fabIunknownIC50 5.89
78 kDa glucose-regulated proteinHSPA5unknownIC50 4.00

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1997-07-11FDA—COLGATE PALMOLIVE

ATC classification

ATC codeTherapeutic hierarchy
D08AE04DERMATOLOGICALS › ANTISEPTICS AND DISINFECTANTS › ANTISEPTICS AND DISINFECTANTS › Phenol and derivatives
D09AA06DERMATOLOGICALS › MEDICATED DRESSINGS › MEDICATED DRESSINGS › Medicated dressings with antiinfectives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Joint dislocation368.5
Seronegative arthritis304.8
Joint stiffness280.5
Prescribed underdose274.6
Wound infection242.3
Walking aid user233.1
Retinitis223.2
Lupus vulgaris221.9
Joint range of motion decreased209.3
Laryngitis205.0
Lupus-like syndrome204.5
Hypercholesterolaemia196.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Triclosan is on its molecule page.

Molecular formulaC12H7Cl3O2
Molecular weight289.54 g/mol
CAS number3380-34-5
InChIKeyXEFQLINVKFYRCS-UHFFFAOYSA-N
PubChem CID5564
OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Triclosan work?

Its molecular targets in DrugCentral include fabI, ENR, fabI and CBR1.

When was Triclosan first approved?

Triclosan was first approved by the FDA in 1997.

What is the chemical formula of Triclosan?

Triclosan has the molecular formula C12H7Cl3O2 and a molecular weight of 289.54 g/mol.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval1997-07-11
AgencyFDA
Targets13
Indications0
FormulaC12H7Cl3O2
DrugCentral ID3631
Interactive profile